Back to Journals » Drug, Healthcare and Patient Safety » Volume 4

Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria

Authors Naing C, Aung K, Ahmed SI, Mak JW

Received 31 May 2012

Accepted for publication 29 June 2012

Published 3 August 2012 Volume 2012:4 Pages 87—92


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Cho Naing,1,3 Kyan Aung,1 Syed Imran Ahmed,2 Joon Wah Mak3

1School of Medical Sciences, 2School of Pharmacy and Health Sciences, 3School of Postgraduate Studies and Research, International Medical University, Kuala Lumpur, Malaysia

Background: For all medications, there is a trade-off between benefits and potential for harm. It is important for patient safety to detect drug-event combinations and analyze by appropriate statistical methods. Mefloquine is used as chemoprophylaxis for travelers going to regions with known chloroquine-resistant Plasmodium falciparum malaria. As such, there is a concern about serious adverse events associated with mefloquine chemoprophylaxis. The objective of the present study was to assess whether any signal would be detected for the serious adverse events of mefloquine, based on data in clinicoepidemiological studies.
Materials and methods: We extracted data on adverse events related to mefloquine chemoprophylaxis from the two published datasets. Disproportionality reporting of adverse events such as neuropsychiatric events and other adverse events was presented in the 2 × 2 contingency table. Reporting odds ratio and corresponding 95% confidence interval [CI] data-mining algorithm was applied for the signal detection. The safety signals are considered significant when the ROR estimates and the lower limits of the corresponding 95% CI are ≥2.
Results: Two datasets addressing adverse events of mefloquine chemoprophylaxis (one from a published article and one from a Cochrane systematic review) were included for analyses. Reporting odds ratio 1.58, 95% CI: 1.49–1.68 based on published data in the selected article, and 1.195, 95% CI: 0.94–1.44 based on data in the selected Cochrane review. Overall, in both datasets, the reporting odds ratio values of lower 95% CI were less than 2.
Conclusion: Based on available data, findings suggested that signals for serious adverse events pertinent to neuropsychiatric event were not detected for mefloquine. Further studies are needed to substantiate this.

Keywords: mefloquine, signal detection, reporting odds ratio, neuropsychiatric events

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes

Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015, 8:121-127

Published Date: 26 February 2015

Antipsychotic agents: efficacy and safety in schizophrenia

de Araújo AN, de Sena EP, de Oliveira IR, Juruena MF

Drug, Healthcare and Patient Safety 2012, 4:173-180

Published Date: 29 November 2012

Evaluation of medication package inserts in Saudi Arabia

Al-aqeel SA

Drug, Healthcare and Patient Safety 2012, 4:33-38

Published Date: 26 March 2012

Analysis on descriptions of precautionary statements in package inserts of medicines

Nabeta K, Kimura M, Ohkura M, Tsuchiya F

Drug, Healthcare and Patient Safety 2012, 4:19-25

Published Date: 24 February 2012

An exploratory study on medications in Qatar homes

Kheir N, El Hajj MS, Wilbur K, Kaissi RML, Yousif A

Drug, Healthcare and Patient Safety 2011, 3:99-106

Published Date: 20 December 2011

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management

Luca Dalle Carbonare, Mirko Zanatta, Adriano Gasparetto, et al

Drug, Healthcare and Patient Safety 2010, 2:121-137

Published Date: 19 August 2010

Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital

Rajakannan Thiyagu, Surulivel R Mallayasamy, Valakkathala Rajesh, et al

Drug, Healthcare and Patient Safety 2010, 2:95-100

Published Date: 30 June 2010

Severe hepatotoxic adverse reaction in a healthy schoolgirl after treatment with flucloxacillin

C-J Törnhage, G Brunlöf, S M Wallerstedt

Drug, Healthcare and Patient Safety 2009, 1:17-19

Published Date: 31 March 2009